CagriSema vs tirzepatide: compare mechanisms, clinical trial weight loss results, dosing, side effects, and approval status in this 2026 guide.
CagriSema has not been tested against tirzepatide in a head-to-head clinical trial, and CagriSema is not FDA-approved for any use. In separate phase 3 studies, CagriSema produced about 20.4% average weight loss at 68 weeks, while tirzepatide 15 mg produced roughly 21% at 72 weeks. Those figures are close enough that many people ask whether CagriSema is better than tirzepatide, and the honest answer is that nobody knows yet.
What Is CagriSema?
CagriSema is an investigational once-weekly injection from Novo Nordisk. It combines cagrilintide, a long-acting amylin analog, with semaglutide 2.4 mg, the GLP-1 receptor agonist sold as Wegovy for weight loss and Ozempic for type 2 diabetes.
The two hormones work through different pathways:
- Cagrilintide mimics amylin, a hormone released alongside insulin that slows stomach emptying and signals fullness in the brain.
- Semaglutide activates GLP-1 receptors, reducing appetite, slowing digestion, and improving blood sugar control.
The dose tested in phase 3 was 2.4 mg cagrilintide plus 2.4 mg semaglutide per week. Novo Nordisk is studying CagriSema in the REDEFINE program, which includes trials in obesity, type 2 diabetes, and cardiovascular risk. CagriSema is not FDA-approved for weight loss, diabetes, or any other indication. Cagrilintide is also studied on its own, which is one reason searches for cagrilintide vs tirzepatide keep appearing alongside CagriSema questions.
What Is Tirzepatide (Zepbound and Mounjaro)?
Tirzepatide is a dual GIP and GLP-1 receptor agonist made by Eli Lilly. It is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes.
Tirzepatide is given as a once-weekly subcutaneous injection, titrated from 2.5 mg up to a maximum of 15 mg. Zepbound was approved by the FDA in November 2023, and single-dose vials are also sold directly by the manufacturer for cash-paying patients. If you are comparing cagrisema vs zepbound or cagrisema vs mounjaro, you are comparing CagriSema with the same molecule, because Zepbound and Mounjaro are both brand names for tirzepatide.
CagriSema vs Tirzepatide: Head-to-Head Comparison
No completed trial randomizes patients to CagriSema or tirzepatide. The table below compares the two drugs on the features that matter most to patients.
| Feature | CagriSema | Tirzepatide (Zepbound / Mounjaro) |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | Amylin analog plus GLP-1 agonist | Dual GIP and GLP-1 agonist |
| FDA status | Investigational; not approved | Approved for obesity and type 2 diabetes |
| Weekly dose | Cagrilintide 2.4 mg + semaglutide 2.4 mg | 2.5 mg to 15 mg |
| Route | Subcutaneous injection | Subcutaneous injection |
| Pivotal weight-loss trial | REDEFINE-1 (68 weeks) | SURMOUNT-1 (72 weeks) |
| Average weight loss in that trial | About 20.4% | About 21% at 15 mg |
| Availability | Clinical trials only | Pharmacies and telehealth, with a prescription |
One indirect clue comes from SURMOUNT-5, a head-to-head trial of tirzepatide against semaglutide 2.4 mg. That study is the reason the question tirzepatide vs semaglutide which is better for weight loss has a fairly clear answer today: tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks. CagriSema pairs semaglutide with cagrilintide to close part of that gap.
Weight Loss Results From Clinical Trials
Trial data are the closest thing available to a cagrisema tirzepatide head-to-head comparison, even though the studies were run separately.
| Trial and treatment | Duration | Average weight loss |
|---|---|---|
| CagriSema (REDEFINE-1) | 68 weeks | 20.4% |
| Semaglutide 2.4 mg (REDEFINE-1 arm) | 68 weeks | About 15% |
| Placebo (REDEFINE-1) | 68 weeks | About 3% |
| Tirzepatide 15 mg (SURMOUNT-1) | 72 weeks | About 21% |
| Tirzepatide vs semaglutide 2.4 mg (SURMOUNT-5) | 72 weeks | 20.2% vs 13.7% |
In REDEFINE-1, 3,417 adults with overweight or obesity received CagriSema, semaglutide 2.4 mg, or placebo for 68 weeks. Participants on CagriSema lost an average of 20.4% of their body weight, and those who stayed on treatment for the full study lost about 22.7%. Semaglutide alone produced roughly 15%, and placebo about 3%.
In SURMOUNT-1, adults without diabetes lost an average of about 21% of their body weight on tirzepatide 15 mg over 72 weeks, compared with about 3% on placebo. The broader topic of semaglutide vs tirzepatide weight loss has been studied far more thoroughly than any comparison involving CagriSema.
Cross-trial comparisons carry real limits. The trials enrolled different populations, ran for different lengths of time, and used different statistical methods, so a few percentage points of difference should not be read as proof that one drug is stronger.
Dosing, Cost, and Availability
- Tirzepatide: available now by prescription as Zepbound or Mounjaro. List prices exceed $1,000 per month, though manufacturer cash-pay vials and savings cards can lower the cost substantially.
- CagriSema: not stocked by any pharmacy. It can only be obtained by enrolling in a clinical trial while Novo Nordisk pursues regulatory approval.
Insurance coverage for tirzepatide varies widely, and Medicare generally does not cover medications prescribed only for weight loss. Compounded tirzepatide has been sold by some pharmacies, but compounded products are not FDA-approved and their availability is restricted.
Novo Nordisk is also developing amycretin, a single molecule that combines amylin and GLP-1 activity in one peptide. Early oral amycretin data showed double-digit weight loss over 12 weeks, but that drug is years behind CagriSema in development. Anyone weighing cagrisema vs amycretin is comparing a late-stage combination product with an earlier-stage candidate. Discussions of cagri peptide vs tirzepatide usually land on the same point: the cagrilintide-based programs have promising data but no approved product yet.
Side Effects and Safety
CagriSema and tirzepatide share the side effects typical of this drug class. The most common are nausea, vomiting, diarrhea, constipation, and abdominal discomfort, which usually appear during dose escalation and ease over time.
CagriSema may also cause injection-site reactions because of the cagrilintide component. Tirzepatide and semaglutide both carry boxed warnings about thyroid C-cell tumors seen in rodents, and both are linked to rare cases of pancreatitis, gallbladder disease, and gastroparesis. Hair thinning is a frequently reported complaint, which is why tirzepatide vs semaglutide hair loss is a common search among people starting treatment.
Neither drug should be used during pregnancy or by anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome. Combining two GLP-1-based drugs, such as CagriSema and tirzepatide, has not been studied and should not be done. Anyone considering either medication should review their medical history and other prescriptions with a licensed healthcare professional.
For now, tirzepatide is the only one of the two that a US patient can actually obtain, and its phase 3 weight-loss data is at least as strong as CagriSema's. CagriSema remains a promising investigational option that may reach the market later this decade. The right choice for any individual depends on medical history, insurance coverage, tolerability, and clinician guidance, not on cross-trial percentages alone.
Frequently Asked Questions
Is CagriSema better than tirzepatide?
No head-to-head trial has compared CagriSema with tirzepatide, so the question cannot be answered definitively. In separate phase 3 studies, CagriSema produced about 20.4% average weight loss at 68 weeks, while tirzepatide 15 mg produced about 21% at 72 weeks. Those numbers look similar, but they come from different trials and are not a direct comparison.
Is CagriSema FDA-approved?
No. CagriSema is an investigational drug and is not FDA-approved for weight loss, type 2 diabetes, or any other use. It is currently available only through clinical trials while Novo Nordisk seeks regulatory approval.
Does CagriSema cause more side effects than tirzepatide?
Both drugs cause similar gastrointestinal side effects, including nausea, vomiting, constipation, and diarrhea. CagriSema may add injection-site reactions from the cagrilintide component. No head-to-head tolerability data exists, so claims that one drug is gentler than the other remain unproven.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.